IRIS
GIANNANTONI, ANTONELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.823
EU - Europa 12.370
AS - Asia 2.278
Continente sconosciuto - Info sul continente non disponibili 46
OC - Oceania 35
SA - Sud America 28
AF - Africa 8
Totale 30.588
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.783
GB - Regno Unito 3.115
IE - Irlanda 3.043
UA - Ucraina 2.227
CN - Cina 2.117
FR - Francia 1.788
SE - Svezia 1.096
IT - Italia 661
DE - Germania 149
FI - Finlandia 144
TR - Turchia 73
EU - Europa 46
CA - Canada 36
AU - Australia 30
RO - Romania 23
VN - Vietnam 22
AT - Austria 20
BR - Brasile 17
IN - India 17
RS - Serbia 16
BE - Belgio 13
NL - Olanda 13
JP - Giappone 11
IM - Isola di Man 7
PL - Polonia 7
BG - Bulgaria 6
CH - Svizzera 6
CL - Cile 5
ES - Italia 5
GR - Grecia 5
NZ - Nuova Zelanda 5
AM - Armenia 4
BD - Bangladesh 4
DK - Danimarca 4
HU - Ungheria 4
RU - Federazione Russa 4
SA - Arabia Saudita 4
AE - Emirati Arabi Uniti 3
AR - Argentina 3
HK - Hong Kong 3
ID - Indonesia 3
MK - Macedonia 3
PE - Perù 3
SG - Singapore 3
TH - Thailandia 3
AL - Albania 2
BY - Bielorussia 2
EG - Egitto 2
IR - Iran 2
JM - Giamaica 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
MA - Marocco 2
MD - Moldavia 2
ZA - Sudafrica 2
BA - Bosnia-Erzegovina 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
HR - Croazia 1
IL - Israele 1
KH - Cambogia 1
LU - Lussemburgo 1
LV - Lettonia 1
MX - Messico 1
NG - Nigeria 1
OM - Oman 1
SL - Sierra Leone 1
Totale 30.588
Salva come PNG Salva come JPEG
Città #
Southend 2.970
Dublin 2.962
Jacksonville 2.519
Fairfield 2.287
Chandler 1.191
Princeton 1.017
Woodbridge 1.016
Wilmington 988
Ashburn 925
Seattle 830
Houston 783
Cambridge 778
Nanjing 680
San Mateo 512
Ann Arbor 307
Beijing 246
Nanchang 223
Boardman 216
San Diego 198
Dearborn 154
Siena 153
Shenyang 147
Helsinki 138
Hebei 119
Changsha 112
Tianjin 112
Jiaxing 92
Norwalk 76
Kunming 72
San Francisco 62
Izmir 58
Shanghai 53
London 45
Rome 33
Jinan 27
Lanzhou 26
Toronto 26
Zhengzhou 23
Dong Ket 22
Guangzhou 21
Milan 21
Vienna 20
Changchun 19
Buffalo 18
Ningbo 18
Fremont 17
Hefei 16
Belgrade 15
Haikou 15
Fuzhou 14
Hangzhou 14
Padova 14
Brussels 12
Canberra 12
Genoa 12
Naples 12
Taizhou 12
Melbourne 11
Turin 11
Bologna 10
New York 10
Palermo 10
Stockholm 10
São Paulo 10
Timisoara 10
Tokyo 10
Amsterdam 9
Bari 8
Frankfurt am Main 8
Senigallia 8
Shaoxing 8
Avondale 7
Douglas 7
Jinhua 7
Sydney 7
Timișoara 7
Castelfranco di Sotto 6
Florence 6
Lappeenranta 6
Limbiate 6
Markham 6
Pasadena 6
Serra 6
Chiswick 5
Kilburn 5
Menlo Park 5
Sofia 5
Trieste 5
Warsaw 5
Brescia 4
Budapest 4
Canelli 4
Chicago 4
Correzzana 4
Edinburgh 4
Madrid 4
Martinsicuro 4
Paris 4
Phoenix 4
Reggio Emilia 4
Totale 22.764
Salva come PNG Salva come JPEG
Nome #
1 hour pad test ha un basso valore predittivo nella diagnosi dell’incontinenza urinaria femminile 252
DIAGNOSI ECOGRAFICA DI DEFICIT SFINTERICO URETRALE NELLA DONNA 160
Pharmacologic goals in interstitial cystitis/bladder pain syndrome 141
1-hour pad test has low predictive value in the diagnosis of women with urinary incontinence 133
Adolescence transitional care in neurogenic detrusor overactivity and the use of OnabotulinumtoxinA: A clinical algorithm from an Italian consensus statement 126
Utilizzo degli Alfa-litici nelle donne con sintomi del basso tratto urinario 121
Usefulness of antibiotic prophylaxis in invasive urodynamics in fertile and in postmenopausal female subjects 116
Endoscopic ballistic lithotripsy in the treatment of Bladder Calculi in patients with Neurogenic Voiding Dysfunction 114
Lower urinary tract symptoms and urodynamic dysfunctions in clinically isolated syndromes suggestive of multiple sclerosis 114
The impact of Mirabegron on sexual function in women with idiopathic overactive bladder 114
Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson's disease: a pilot study 114
Sensitivity and specificity of one-hour pad test as a predictive value for female urinary incontinence 113
Urgency of micturition and detrusor contractility in men with prostatic obstruction and overactive bladders 112
Desmopressin in the treatment of nocturia in patients affected by Parkinson's disease 112
The Splicing Factor PTBP1 Promotes Expression of Oncogenic Splice Variants and Predicts Poor Prognosis in Patients with Non-muscle-Invasive Bladder Cancer 110
Cystoman® and calculi: a good alternative to standard therapies in preventing stone recurrence 109
Thalidomide as therapy for the chronic pelvic pain syndrome (CPPS) 108
Desmopressin in the treatment of nocturia in patients affected by neurogenic bladder 107
Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study 106
Resonance® metallic stent in patients with ureterocutaneostomies 104
Bacillus Calmette-Guérin versus Gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study 104
Single-session supine bilateral percutaneous nephrolithotomy 103
Dermatomyositis Associated with Testicular Germ Cell Cancer 103
Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System 102
Urodynamic findings and functional outcomes after laparoscopic sacrocolpopexy for symptomatic pelvic organ prolapse 101
Two-year efficacy and safety of botulinum A toxin intravesical injections in patients affected by refractory painful bladder syndrome 100
Botulinum-A toxin injections into the detrusor muscle reduce nerve growth factor bladder tissue levels in patients affected by neurogenic detrusor overactivity. 100
PUMA vs Romanzi in the detection of female bladder obstruction and detrusor contractility. 100
An Updated Systematic Review and Statistical Comparison of Standardised Mean Outcomes for the Use of Botulinum Toxin in the Management of Lower Urinary Tract Disorders 100
Botulinum A toxin intravesical injections improves sexual function in female patients affected by neurogenic detrusor overactivity 99
Sequential intravesical bacillus Calmette-Guerin and electromotive mitomycin-C for high risk superficial bladder cancer: a prospective controlled study 99
Urological dysfunctions and upper urinary tract involvement in multiple sclerosis (MS) patients 99
Does the neobladder filling modulate soleus H reflex? 99
Prostasomes and prostate cancer 99
Association between selenium and lycopene supplementation and incidence of prostate cancer: Results from the post-hoc analysis of the procomb trial 97
Long-term efficacy of the trans-obturator and retropubic mid-urethral slings for stress urinary incontinence: update from a randomized clinical trial 97
Bladder and urethral sphincter function after radical retropubic prostatectomy: A prospective long-term study 96
A prospective randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease 96
Dyssynergia or asynergia? 96
Lower urinary tract symptoms and urodynamic dysfunctions in clinically isolated syndromes suggestive of multiple sclerosis 95
Intravesical resiniferatoxin versus botulinum-A toxin injections for the treatment of neurogenic detrusor overactivity. 95
Intravesical resiniferatoxin versus capsaicin in the treatment of detrusor hypereflexia in spinal cord injured patients 94
Clean intermittent catheterization and prevention of renal disease in spinal cord injury patients 94
Treatment of neurogenic bladder in spinal cord injury (SCI) patients by means of clean intermittent catheterization (CIC): prevention of renal disease 93
Nerve Growth Factor bladder tissue levels in patients with benign prostatic hyperplasia and detrusor overactivity treated with tamsulosin. 93
Editorial comment on: Complete continence after botulinum neurotoxin type a injections for refractory idiopathic detrusor overactivity incontinence: patient-reported outcome at 4 weeks 93
Patient-reported outcomes in bladder pain syndrome: qui auget dolorem, auget et scientiam (as pain increases, so increases knowledge) 92
Psychological investigation in spinal cord injury patients. 92
Must colposuspension be associated with sacropexy to prevent postoperative urinary incontinence? 92
A practical approach to the management of nocturia 92
Voiding dysfunction after radical retropubic prostatectomy: More than external urethral sphincter deficiency 91
“Efficacy and tolerability of fesoterodine fumarate in the treatment of overactive bladder symptoms in patients affected by Multiple Sclerosis: Long term follow up” 91
Urinary symptoms and sexual dysfunction in patients affected by multiple sclerosis 91
Intradetrusorial Botulinum Toxin in Patients with Multiple Sclerosis: A Neurophysiological Study 91
Linking age, cystocele and abdominal straining 91
OnabotulinumtoxinA intradetrusorial injections modulates bladder expression of NGF, TrkA, p75 and TRPV1 in patients with detrusor overactivity 90
Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group 90
Pharmacotherapy of overactive bladder: epidemiology and pathophysiology of overactive bladder 90
Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin 90
Intravesical administration of botulinum A toxin in spinal cord injured patients. Suburothelial versus intradetrusorial injections 90
Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis 90
New frontiers in intravesical therapies and drug delivery 89
Abdominal versus Laparoscopic sacrocolpopexy: a randomized controlled trial 88
Six-year follow-up of intradetrusorial injections of botulinum toxin type A in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results 88
Intermittent catheterization with a prelubricated catheter in spinal cord injured patients: a prospective randomized crossover study 88
Linking age, cystocele and abdominal straining 87
Urinary symptoms and sexual dysfunction in patients affected by multiple sclerosis 86
Voiding Dysfunction in Patients With Spinal Cord Lesions at the Thoraco-Lumbar Vertebral Junction 86
Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study 86
Female sexuality in chronic pelvic pain 86
Serenoa repens + selenium + lycopene vs tadalafil 5 mg for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: a Phase IV, non-inferiority, open-label, clinical study (SPRITE study) 86
Extraction and determination of oxybutynin in human bladder samples by reversed-phase high performance liquid chromatography 85
Clinical and neurophysiologic study of botulinum A toxin effect on neurogenic and idiopathic detrusor overactivity 85
Botulinum A toxin modulates afferent fibers in neurogenic detrusor overactivity 84
The Efficacy and Safety of Duloxetine in a Multidrug Regimen for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 84
Assessment of botulinum A toxin high affinity SV2 receptors on normal human urothelial cells. 83
Preoperative MUCP and VLPP Did Not Predict Long-Term (4-Year) Outcome after Transobturator Mid-Urethral Sling 83
Normal human urothelial cell lines express onabotulinumtoxinA SV2 high affinity receptors 83
Intravesical electromotive Mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study 83
INFILTRAZIONI INTRADETRUSORIALI DI ONABOTULINUMTOXINA IN PAZIENTI AFFETTI DA SINDROME DELLA VESCICA IPERATTIVA: BEST- PRACTICE MANAGEMENT 83
Chronic prostatitis: How to give our best without apposite vagueness 83
Tension-free vaginal tape (TVT) and trans-obturator suburethral tape (TOT) a prospective randomized trial 83
Sequential BCG and electromotive mitomycin versus BCG alone for high- risk superficial bladder cancer: a randomised controlled trial 83
Clean intermittent catheterization and prevention of renal disease in spinal cord injury patients 83
Triage of functional, female and neuro-urology patients during and immediately after the COVID-19 outbreak 83
Comparative bladder wall tissue levels of resiniferatoxin 82
Female sexual dysfunction in urogenital prolapse surgery: colposacropexy vs hysterocolposacropexy 82
Stability of Resiniferatoxin stock solutions 81
NERVE GROWTH FACTOR BLADDER TISSUE LEVELS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA AND DETRUSOR OVER ACTIVITY TREATED WITH TAMSULOSIN 81
OnabotulinumtoxinA intradetrusorial injections modulates bladder expression of NGF, TrkA, p75 and TRPV1 in patients with detrusor overactivity 81
Is the one-hour pad-test useful in the assessment of urinary stress incontinence? 81
Intravesical resiniferatoxin versus botulinum-A toxin injections in patients with neurogenic detrusor overactivity: a prospective randomized study 81
Intraprostatic Botox injection in patients with severe benign prostatic hyperplasia. A multicenter study. 80
Intravesical resiniferatoxin versus botulinum A toxin injections for the treatment of neurogenic detrusor overactivity 80
Botulinum A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms 80
Preoperative MUCP and VLPP failed to predict outcome in patients who underwent transobturator mid-urethral slings 80
Hypospadias classification and repair: the riddle of the sphinx 80
Thalidomide as therapy for the chronic pelvic pain syndrome (CPPS) 80
Desmopressin in the treatment of nocturia in patients affected by neurogenic bladder 80
Usefulness of antibiotic prophylaxis in invasive urodynamics in fertile and postmenopausal female subjects. 80
Totale 9.643
Salva come PNG Salva come JPEG
Categoria #
all - tutte 102.337
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 102.337
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.947 0 0 0 0 0 0 0 0 0 419 854 674
2019/20208.636 1.307 237 465 1.404 443 672 854 1.177 554 762 154 607
2020/20215.351 402 700 53 679 116 855 184 1.163 94 659 104 342
2021/20224.737 257 459 556 377 31 133 66 254 187 591 342 1.484
2022/20236.043 542 162 961 1.178 549 1.433 60 360 532 67 115 84
2023/20242.948 152 87 273 92 83 990 1.130 56 20 65 0 0
Totale 31.811